Save time and money with
Med Tech Market Research

MedTech Business intelligence
supplied by GlobalData

Exelon (Alzheimer’s disease) — Forecast and market analysis to 2022

Publication Date:  September 2013

Go to the report store >>


There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Exelon (rivastigmine, rivastigmine tartrate), which is manufactured and marketed by Novartis, is a reversible ChEI indicated for the treatment of mild to moderate dementia of the Alzheimer's type. The exact mechanism of action (MOA) of rivastigmine is unknown, but it is thought to increase ACh concentrations through reversible inhibition of AChE by hydrolysis.


  • Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Exelon including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Exelon for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and India.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for AD.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Exelon performance.
  • Obtain sales forecast for Exelon from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, China and India).

More information & buy >> Exelon (Alzheimer’s Disease) - Forecast and Market Analysis to 2022
(from GlobalData)



To top



To top